Veralto Corporation (NYSE: VLTO) — Danaher’s Highest-Return Orphan: A ~19%-ROIC Water Compounder De-Rated for Being “Merely” Mid-Single-Digit

Independent equity research. Report date: July 4, 2026. Price reference: $92.55 (July 2, 2026).

⚡ Claude’s Take

This is the author’s own independent opinion and general information, not investment advice. The analysis that follows takes no position and sets no price target; only this section expresses a view.

Verdict: HOLD / accumulate-on-weakness. A genuine quality compounder at a fair-to-attractive price — but not a table-pounding buy at $92. Real margin of safety opens sub-mid-$80s; I would be a committed accumulator sub-$85 and a buyer sub-$80. Fair-value zone ≈ $95–$105 on ~22–24x FY26 adjusted EPS of ~$4.24; the cheapest-ever valuation gives you a defensible entry, not a screaming one.

Veralto is the cleanest, highest-return business Danaher ever spun off, and the market is bored of it. Strip away the noise and you own a ~$5.5B-revenue, ~60%-gross-margin, ~23%-operating-margin franchise that is 61% recurring razor/razorblade consumables and service, throws off ~$1B of nearly-GAAP-pure free cash flow at ~108% conversion, carries almost no goodwill drag (so its ~19% reported ROIC is roughly double its ~8–9% cost of capital and dwarfs every serial-acquirer peer — Danaher ~6%, Roper ~6%, Xylem ~8%, Ecolab ~13%), and sits on a fortress balance sheet at ~0.5x net leverage with $2B of cash. It is two consolidated oligopolies stapled together: #1 water-quality analytics (Hach), top-2 municipal UV (Trojan), and #1 continuous-inkjet marking-and-coding (Videojet), each protected by installed-base switching costs, razor/blade consumable attach, and — in water — EPA-approved-method regulatory captivity. This is a real franchise, not a story.

So why only HOLD? Because the thing the market wants — growth — is the one thing this business doesn’t have in abundance. Organic revenue runs mid-single-digit (~4–6%), and the celebrated “double-digit adjusted-EPS” record leans heavily on non-volume levers: price (~200bps), margin fall-through, a falling tax rate (24.5%→low-20s since spin), delevering, and a newly-started buyback. That is a perfectly good algorithm, but it is a compounding engine, not an acceleration engine, and it prices as such. The tape agrees: VLTO loads negative on the Growth and Momentum factors, positive on Quality, and low on beta (~0.8) — its factor-cousins are Dividend-Aristocrat and Low-Vol ETFs and S&P Global. It has round-tripped from a ~$113.60 peak (Oct-2024) back to ~$92.55 as the multiple compressed from ~21x to ~16.8x EV/EBITDA while earnings rose. That’s a de-rating of a good business, not a broken one — which is exactly why it’s interesting near its cheapest-ever multiple (12th percentile P/E on its own short history), and exactly why it isn’t a bargain: there is no catalyst, insiders aren’t buying (the CEO is a programmatic 10b5-1 seller), and $2B of idle cash is deployment risk as much as it is optionality.

Framing: out-of-favor quality-compounder-at-a-reasonable-price — NOT a falling knife (the business is stable and growing) and NOT a momentum trade (it’s the opposite). You are being paid a fair, not generous, price to own the best-returning water name in the group and wait for either a growth inflection (PFAS/emerging-contaminant monitoring, water reuse, data-center water) or a re-rate toward its Ecolab-quality peers. Conviction: medium. Single bullish trigger: organic growth durably inflects above ~6% as the secular water tailwinds convert to orders (watch In-Situ/PFAS and data-center water). Single bearish trigger: organic decelerates below ~3% with PQI packaging/color weakness proving structural, or management spends the $2B cash hoard on a large, dilutive, full-priced deal that drags ROIC toward the peer-group trap. Tag: “Danaher’s best-returning orphan, priced like it’s boring.”

📈 Stock Price Action — Since the October-2023 Spin

Veralto has been public for only ~2.75 years (distributed from Danaher and first traded ~Sept 27, 2023, near $80). In that window it has round-tripped: a first-trade base near ~$80 → an all-time high of ~$113.60 (Oct-18-2024, +42%) → back to ~$92.55 today (Jul-2-2026), roughly 18% below the peak. The 52-week range is ~$82.23–$109.75. The pattern is a de-rating, not an earnings decline: adjusted EPS rose from ~$3.55 (FY23) to ~$3.90 (FY25) while the multiple compressed from ~21x toward ~16.8x EV/EBITDA.

Cycle narrative. (1) The immediate post-spin slide to ~$67.5 was textbook orphaned-spin-off mechanics — a ~$20B water business sold by holders who wanted Danaher, not water analytics. (2) Through 2024 the market re-rated the quality — the balance sheet delevered fast, gross margin expanded ~200bp, and a “mini-Danaher” narrative carried the stock to ~$113.6 at ~21x EBITDA. (3–5) From late 2024 it ground lower in three legs: each time growth printed mid-single-digit (good, not great), the multiple leaked, aggravated by the April-2025 tariff shock and a market rotating out of low-beta, low-growth quality. (6) The recent bounce is off the stock’s cheapest-ever valuation. In every row the price move is a Fact (market price history); the attributed driver is Interpretation, cross-referenced against earnings dates, the tariff timeline, and the multiple trend.

1. Executive Summary

Veralto is the water-quality and product-identification company distributed to shareholders by Danaher on September 30, 2023 (one VLTO share per three DHR shares). It is a ~$5.5B-revenue, ~$22B-market-cap franchise that operates two roughly-equal-margin segments: Water Quality (WQ, ~60% of sales) — Hach analytics, Trojan UV disinfection, ChemTreat industrial water treatment, McCrometer — and Product Quality & Innovation (PQI, ~40%) — Videojet/Linx marking & coding, Esko packaging software, X-Rite/Pantone color standards, TraceGains. Roughly 61% of revenue is recurring consumables, service, and software off a large installed base — the razor/razorblade model Danaher perfected.

The financial profile is elite for an industrial: gross margin ~60% (up from 56.7% at spin), operating margin ~23%, both segments earning ~25% operating margins, EBITDA margin ~24.6%, FCF ~$1B at ~108% of net income on trivial ~1.1%-of-sales capex, and reported ROIC ~19% — roughly double an ~8–9% cost of capital and the highest in its quality-industrial cohort. The decisive quality tell is that, unlike Danaher, Ecolab, or Roper, Veralto carries a modest goodwill base (~$2.84B) and negligible finite-lived intangibles (~$216M net), so acquisition-intangible amortization is only ~$36M/year and GAAP EPS (~$3.76 FY25) sits within ~4% of adjusted EPS (~$3.90). The earnings are “real”; there is no giant non-GAAP bridge to squint through. The balance sheet is a fortress: net leverage ~0.5x, $2.0B cash, a fully undrawn $1.5B revolver, and investment-grade laddered notes.

The industry backdrop is favorable. Water analytics (Hach #1, ~16% share), UV disinfection (Trojan top-2, ~15%-CAGR market), and marking & coding (Videojet #1 in continuous inkjet) are consolidated oligopolies with regulatory and switching-cost moats and multi-year secular tailwinds (EPA PFAS rule, Lead & Copper Rule, water reuse, packaging serialization). The one structurally weaker business is ChemTreat, a subscale player in a $40B industrial-water-chemicals market dominated by Ecolab’s Nalco.

The debate is entirely about price and growth trajectory, not quality. Organic growth is mid-single-digit; the double-digit adjusted-EPS record is powered by price, margin, a falling tax rate, delevering, and a newly-authorized $750M buyback rather than volume. At ~16.8x EV/EBITDA, ~24x P/E, and a ~4.6% FCF yield — the cheapest levels of its short public life — the market is underwriting continued mid-single-digit organic growth and ~10% EPS compounding with no re-rating. That is a reasonable-to-conservative bar for a ~19%-ROIC, 61%-recurring, 0.5x-levered franchise, but there is no near-term catalyst, insiders are net sellers, and $2B of idle cash is a double-edged sword. High-quality, cheap-to-fair, catalyst-light.

2. Business Overview

What Veralto does. Veralto sells the instruments, consumables, software, and services that ensure water is safe and that consumer and industrial products are correctly made, marked, and traced. It is, in essence, two former Danaher platforms — “Water Quality” and “Product Identification” — combined and spun out as a standalone, ~16,000-employee public company headquartered in Waltham, Massachusetts.

Segment 1 — Water Quality (WQ): ~60% of revenue, ~25% operating margin. FY2025 segment revenue $3,321M (up from $3,138M FY24 and $3,039M FY23); segment operating profit $844M at a 25.4% margin (up from 24.5% and 24.0%). WQ measures, analyzes, and treats water across municipal, industrial, commercial, research, and natural-resource applications. Key franchises:

• Hach — the global #1 in water-quality analytics: benchtop and process instruments, sensors, and the proprietary reagents/standards they consume (a razor/razorblade annuity). Hach serves more than 149,000 customers with no meaningful concentration.
• Trojan Technologies — a top-2 municipal UV-disinfection franchise (and increasingly advanced oxidation for emerging contaminants and reuse). Longer-cycle, more capital-equipment-weighted; Q1-2026 bookings ship as late as Q4-2027.
• ChemTreat — service-intensive industrial water-treatment chemistry delivered by on-site engineers; competes against Ecolab/Nalco and Kurita.
• McCrometer / OTT HydroMet / In-Situ — flow measurement and environmental/hydrological monitoring.

Segment 2 — Product Quality & Innovation (PQI): ~40% of revenue, ~25% operating margin. FY2025 segment revenue $2,182M (up from $2,055M and $1,982M); operating profit $549M at 25.2% (vs 25.7% and 23.8%). PQI keeps products correctly marked, coded, inspected, and color-accurate:

• Videojet (+ Linx) — the #1/co-#1 in continuous-inkjet (CIJ) marking & coding: the printers that put lot codes, expiry dates, and serialization marks on packaging, plus the proprietary inks and fluids they consume (again razor/razorblade). Line-downtime risk makes the installed base extremely sticky.
• Esko — packaging prepress and workflow software (subscription/recurring).
• X-Rite / Pantone — color measurement hardware and the Pantone color-standard IP (a de facto global standard licensed across design, apparel, and packaging).
• TraceGains — cloud supply-chain/formulation/compliance software for food & beverage (acquired 2024, >20% grower, ~80% gross margin).

How it makes money / revenue quality. ~61% of FY2025 revenue ($3,359M) is recurring — consumables (reagents, inks, standards), service/maintenance, and software subscriptions — split ~$1,966M WQ / ~$1,393M PQI. The remaining ~39% is instruments/equipment that seeds the recurring stream. This is a genuine installed-base annuity: the customer buys an analyzer or a coder once and then buys Veralto’s proprietary consumables and service for a decade-plus, often within a regulatorily-validated workflow. Geographic mix (FY2025): North America ~48% ($2,639M), Western Europe ~22.5% ($1,241M), high-growth markets ~27.3% ($1,505M), other developed ~2%. End markets: municipal and industrial water, food & beverage, pharmaceutical, consumer packaged goods, and packaging/print. R&D is ~$266M (4.8% of sales).

Verdict: A diversified, recurring-revenue-heavy portfolio of category-leading franchises with essentially no customer concentration and balanced end-market and geographic exposure. The business quality is high and unusually well-diversified for a company this size; the honest caveat is that “diversified across two segments and five franchises” is also why no single growth vector is large enough to move the ~$5.5B top line more than mid-single-digit.

3. Industry Dynamics

Veralto plays in several distinct markets, most of them consolidated, high-return, and structurally attractive.

Water-quality analytics & instruments (~$4–5B, ~5.5% CAGR). A consolidated market in which Hach is #1 at ~16% share and the top five hold ~40%. Roughly 35% of market value is recurring consumables (reagents, standards) and ~45% instruments — a razor/razorblade structure with real switching costs, since EPA- and internationally-approved test methods are written around specific instruments and reagents. Demand is driven by tightening water-quality regulation, industrialization, and the shift from lab to continuous online monitoring. Competitors: Xylem (YSI/OTT), Thermo Fisher, Endress+Hauser, Emerson, ABB. Structurally good.

UV disinfection (~$3.9B, ~15% CAGR). The fastest-growing water pool, pulled by PFAS/advanced-oxidation treatment, water reuse/recycling, and the replacement of chlorine-based disinfection. Trojan is a top-2 municipal player against Xylem/Wedeco (~22% share) and SUEZ. More project/capital-equipment-weighted (thinner recurring), but the demand curve is excellent. Structurally very good.

Industrial water-treatment chemicals (~$40B, ~4.5–5.7% CAGR). A large, fragmented, chemically-competitive market dominated by Ecolab/Nalco (~$4.2B water revenue), Kurita, Solenis, Veolia, and Kemira. Veralto’s ChemTreat (~$0.5B+) is a subscale, service-differentiated specialist — it wins on embedded on-site engineering and switching costs but is cost-disadvantaged versus Nalco’s scale. This is the structurally weakest market Veralto competes in and the one place a larger competitor has genuine capital-cycle heft against it.

Marking & coding (~$7.8B → ~$13.8B by 2035). GDP-plus growth tied to packaging volume, SKU proliferation, and serialization/traceability/expiry-date mandates. Continuous inkjet (CIJ) is ~38–44% of the market and Videojet is #1/co-#1; the tier-1 trio of Videojet (VLTO), Markem-Imaje (Dover), and Domino (Brother) holds ~36% of case-coding. The moat is scale + installed-base switching costs (a stopped coding line stops the whole packaging line) + razor/blade ink consumables. Structurally good, low-cyclicality.

Color & packaging software (Esko, X-Rite/Pantone). Niche, high-margin, standards-and-software-driven, with Pantone’s color IP a genuine intangible moat. Small but sticky.

Regulatory and secular tailwinds (the demand floor). The water franchises benefit from apolitical, multi-year regulatory mandates: the EPA’s 2024 PFAS drinking-water rule, the Lead & Copper Rule Improvements (lead-service-line replacement), water reuse/recycle driven by scarcity, and IIJA water funding (a fading marginal tailwind, not the core engine, with reauthorization uncertain post-Sept-2026). Marking & coding rides packaging serialization and food-traceability mandates. Crucially, most of this demand is operating-expense-driven (consumables, compliance) rather than lumpy municipal capex, which insulates Veralto from the water-utility budget cycle that whipsaws pure capital-equipment vendors.

Capital-cycle read (Marathon). Every market Veralto plays in is supply-side rational: consolidated, oligopolistic, high-return incumbents with no flood of new capacity entering the proprietary, regulation-locked pools. Water analytics and UV sit in a favorable part of the cycle (regulatory demand pull, no overinvestment); marking & coding is steady GDP+. The one exception is industrial water chemicals, where Ecolab’s Nalco has scale advantages ChemTreat cannot match.

Verdict: structurally good-to-very-good industries. Water analytics, UV, and marking & coding are attractive, consolidated, moated, mid-single-digit-growth markets with genuine regulatory tailwinds. ChemTreat is the structurally weakest exposure. Net: a good set of industries that smooths cyclicality and supports high returns — but mid-single-digit, not high-growth, end-markets.

4. Competitive Position

Veralto’s moat is real, financially validated, and segment-specific — strongest in Hach and Videojet, moderate in Trojan, weakest in ChemTreat.

Name the moat (Greenwald taxonomy).

• Hach / water analytics — intangibles + customer captivity + regulatory captivity (wide). The installed base of analyzers pulls proprietary reagents and standards (razor/razorblade), and — decisively — EPA-approved and internationally-standardized test methods are written around specific Hach instruments and chemistries. Switching means re-validating a regulated method: costly, slow, and career-risky for the water manager who specifies it. This is a genuine, durable barrier; it shows up as ~25% segment margins and pricing power.
• Videojet / Linx — economies of scale + switching costs + razor/blade (wide). A stopped coder stops the entire packaging line, so customers value uptime, service density, and reliability over price; the installed base then consumes Videojet’s proprietary inks and fluids for years. Global service scale (a field force that can be on-site fast) is a scale barrier smaller rivals struggle to replicate. Serialization/traceability mandates add a regulatory tailwind.
• Trojan / UV — engineering scale + validated-dose regulatory (moderate). Trojan’s reference base and validated UV-dose engineering are real advantages, but the business is more project/capital-equipment-weighted with a thinner recurring tail, so the moat is narrower than Hach’s.
• Esko / X-Rite / Pantone — intangible standards + software switching (niche but strong). Pantone is a de facto global color standard; Esko workflow software has subscription lock-in. Small, high-margin, sticky.
• ChemTreat — service/switching-cost only (narrow). Embedded on-site engineers create switching costs, but ChemTreat is subscale and cost-disadvantaged against Ecolab/Nalco. This is the one franchise where the moat is thin and a larger competitor has structural scale advantages.

The financial proof the moat is real. A moat claim is only credible if a financial outcome would deteriorate without it. Veralto’s do: ~60% gross margins, ~25% segment operating margins sustained through a spin, a tariff shock, and inflation; ~200bp of gross-margin expansion in three years; ~19% ROIC; and demonstrated ~200bps+ of annual pricing without volume loss. These are the signatures of pricing power and customer captivity, not of a commodity vendor.

The Veralto Enterprise System (VES). VES is the company’s Danaher-Business-System clone — a lean/kaizen operating, pricing, procurement, and M&A-integration playbook. Pressure-tested against Greenwald, VES is not itself a barrier to entry (a competitor is not excluded from a market because Veralto runs kaizen); it is an execution and capital-allocation flywheel that amplifies the underlying switching-cost and scale moats and powers disciplined tuck-in M&A. Credit it as a real, repeatable advantage — but the durable moat is the installed base, the regulatory method lock-in, and the consumable attach; VES makes the most of them.

Verdict: a genuine, financially-validated, segment-specific moat — wide in Hach and Videojet (installed base + switching costs + razor/blade + regulatory captivity), moderate in Trojan, niche-strong in color/software, and narrow in ChemTreat. Net, materially higher-quality and higher-return than a hardware-led water peer like Xylem, and, on returns per dollar of capital, better than the goodwill-laden serial acquirers (Danaher, Roper, Ecolab). The weak link is ChemTreat’s subscale position against Nalco.

5. Growth History and Forward Opportunities

Historical growth. Revenue: $4,870M (FY22, carve-out basis) → $5,021M (FY23) → $5,193M (FY24) → $5,503M (FY25), a ~4.2% reported CAGR of which the bulk is organic (~4–5% “core”) plus small FX and bolt-on M&A. FY2025 reported growth was WQ +5.8% and PQI +6.2% (including FX/M&A). Adjusted EPS grew ~10% in both FY24 and FY25 — a clear illustration of the model: mid-single-digit organic revenue converted into double-digit EPS via margin expansion, price, a falling tax rate, delevering, and (from FY26) buyback.

The quality of that growth — the central tension. The revenue growth is high-quality (recurring, priced, moated) but slow. The EPS growth is faster but lever-driven: decompose the ~10% and a meaningful share comes from price (~200bps), incremental margin fall-through (30–35%), a tax rate that fell from ~24.5% at spin to the low-20s, lower interest as net debt fell from $1.9B to $0.6B, and now share repurchase — not from unit volume. This is a legitimate compounding algorithm (Danaher runs the same one), but investors should not confuse ~10% EPS growth with ~10% demand growth; the underlying volume engine is mid-single-digit.

Forward opportunities (the bull’s growth case).

• PFAS and emerging-contaminant monitoring — the 2024 EPA PFAS rule and tightening limits drive demand for analytics (Hach, In-Situ) and treatment (Trojan advanced oxidation). Real, multi-year, but not yet a quantified standalone revenue line.
• Water reuse / recycle — Trojan UV is directly levered to the global reuse buildout (Europe, Middle East, water-scarce US regions).
• Data-center water — liquid/warm-water cooling increases Veralto content (precision dosing, ultra-low-TOC analytics, high-purity disinfection); management engages from preconstruction. Still “a very small portion” of WQ today — optionality, not a current driver.
• Industrial WQ — mid-to-high-single growth tied to semiconductors, power, and mining.
• Marking & coding acceleration — steady CPG demand plus serialization; new UV laser marking for flexible film.
• Tuck-in M&A — In-Situ (~$427M, WQ, 2026), GlobalVision (PQI packaging-inspection AI, 2026), TraceGains (2024), AQUAFIDES — the VES-improvable, razor/razorblade, direct-to-customer funnel. ~$1B deployed by Q1-2026 with a 0.5x-levered balance sheet and $2B cash for more.
• Cost-optimization program (new Q1-2026, benefits from 2027) — additive to the fall-through algorithm; size undisclosed.

Verdict: high-quality but mid-single-digit growth. The demand growth is durable, recurring, and moated but structurally mid-single-digit; the double-digit EPS record is real but lever-assisted. The secular water tailwinds (PFAS, reuse, data-center water) are genuine call options on a faster growth rate — but they are optionality the base case does not require and the market does not yet pay for. This is a compounder, not a grower.

6. Financial Quality

Veralto is, financially, the cleanest business in the water/quality-industrial complex, and its quality shows up where it matters most — in returns on capital.

Revenue & margins. Sales grew ~4.2%/yr FY22→FY25 to $5,503M. Gross margin expanded from 56.7% to 59.9%; operating margin held ~23%; EBITDA margin ~24.6%. Both segments earn ~25% operating margins. This is a ~60%-gross-margin, ~23%-operating-margin, ~61%-recurring franchise — an unusually high-quality margin structure for a company with mid-single-digit growth.

Earnings quality — the anti-Danaher. This is the single most important differentiator. Unlike its parent, Veralto’s GAAP earnings are not materially distorted by acquisition-intangible amortization. It carries $2,838M of goodwill (which does not amortize) but only ~$216M of net finite-lived intangibles (plus ~$308M of indefinite-lived trademarks), so annual acquisition-intangible amortization is just ~$36M (FY25). The result: FY25 GAAP diluted EPS $3.76 vs. company adjusted EPS ~$3.90 — a gap of only ~$0.14 (~4%), against Danaher’s ~55% GAAP-to-adjusted gap. Stock-based compensation is small ($74M, ~1.3% of sales) and correctly excluded from free cash flow. You do not need a heroic non-GAAP bridge to value Veralto; the earnings are essentially real.

Cash generation. Asset-light in the extreme: FY25 capex was just $63M (1.1% of sales). Operating cash flow $1,077M, free cash flow $1,014M, FCF/net income ~108% — clean conversion, with cash exceeding GAAP net income. FCF/share ~$4.08; on ~$22B market cap that is a ~4.6% FCF yield.

Returns on capital — the differentiator. Reported ROIC ~18.8% (FY25), down from ~20–25% in prior years but still roughly double an ~8–9% WACC. This is decisive: because Danaher spun Veralto off with a modest goodwill base rather than a $60B one, Veralto earns genuinely high returns on the capital actually invested — versus DHR (~6% consolidated ROIC), Ecolab (~13%), Roper (~6%), and Xylem (~8%), all dragged down by decades of premium-priced M&A. ROE (~70%) is distorted by thin/negative tangible equity and is not meaningful; ROIC is the right lens and it is excellent.

Balance sheet. Pristine and rapidly de-levered. Net debt fell from $1,867M (FY23) to $642M (FY25); net-debt/EBITDA 1.52x → 1.16x → ~0.5x (~0.6x including capital leases). Cash $2.0B, total debt ~$2.67B (ex-leases) in laddered investment-grade notes (5.50% due 2026 — refinanced June-2026 with $725M 4.85% notes due 2032 — 5.35% due 2028, 4.15% euro due 2031, 5.45% due 2033), interest coverage ~14x, and a fully undrawn $1.5B revolver. Tangible book is slightly negative (~−$1/share), goodwill-driven and immaterial given the cash-generative model.

Verdict: economics are excellent and improve modestly with scale (gross margin +320bp in four years, ~30–35% incremental fall-through, ~19% ROIC, ~108% FCF conversion, negligible amortization, fortress balance sheet). The only honest caveat is growth: this is high-quality, cash-generative, mid-single-digit-growth economics — a compounder, not a rocket.

7. Capital Allocation

The framework. Veralto runs the Danaher-lineage capital-allocation playbook: disciplined tuck-in M&A first, a low-payout-but-growing dividend, buyback as residual, and delevering to preserve optionality. The proof it is disciplined is in both the deals and the incentives.

M&A. Post-spin the company delevered fast (net debt $1.9B → $0.6B), then deployed capital selectively: TraceGains (~$349M, Oct-2024; >20% grower, ~80% gross margin, food & beverage SaaS), AQUAFIDES (small, 2025), In-Situ (~$427M, 2026; environmental water measurement, ~50% gross margin, ~8% historical growth targeted toward low-double-digit under Veralto), and GlobalVision (2026; packaging-inspection AI complementing Esko/TraceGains). ~$1B deployed by Q1-2026. All are razor/razorblade, direct-to-customer, VES-improvable businesses — precisely the funnel the model is built for. FY2025 itself was M&A-quiet (zero material deals), which is why cash built from $1.1B to $2.0B: the balance sheet now holds meaningful dry powder.

Dividend & buyback. The board initiated a dividend post-spin and raised it +18% to $0.13/quarter in Q4-2025 — a deliberately low ~11–12% payout that preserves M&A firepower. In November 2025 the board authorized the company’s first-ever $750M open-ended buyback, largely spent by Q1-2026. Buyback is residual/opportunistic, not a primary policy.

Incentive alignment (the proxy). Veralto’s compensation is genuinely per-share- and returns-oriented — a textbook Danaher design that discourages empire-building:

• Annual bonus (70% Company Financial Factor + 30% personal): 40% Adjusted EPS + 40% Core (organic) Revenue Growth + 20% Free-Cash-Flow Conversion. In 2025 the company replaced Adjusted Operating Profit with Adjusted EPS and shifted weight toward growth — every metric per-share, organic, or cash.
• Long-term equity (50% PSUs / 25% options / 25% RSUs): PSUs vest on relative TSR vs. the S&P 500 over ~3 years (25th pctile = 50%, 50th = 100%, 75th+ = 200%) with a ±10% 3-year-average-ROIC-change modifier.
• No revenue-dollars, absolute-EBITDA, or deal-count metric anywhere. CEO Jennifer Honeycutt’s 2025 total comp was $14.8M (90.2% at-risk); CFO Sameer Ralhan $5.3M. The one soft spot: ROIC is only a ±10% modifier on PSUs rather than a primary gate, and relative TSR is the dominant LTI driver — so returns discipline is secondary, and a large full-priced deal that grows EPS could still be rewarded if it doesn’t dent 3-year ROIC much.

Insider behavior. A negative-to-neutral tell: across 135 Form 4s since the spin there is essentially no discretionary open-market buying — a single nominal 9-share director purchase. CEO Honeycutt and other officers are recurring net sellers under Rule 10b5-1 plans (planned diversification, not discretionary dumps). Insiders as a group hold <1% of shares; there is no founder/Rales block (Vanguard 11.8%, BlackRock 9.6%, T. Rowe 4.3% are the top holders). This is a professionally-managed spin-off, not an owner-operator with skin in the game.

Verdict: management has allocated capital intelligently and is incentivized to keep doing so — disciplined tuck-ins, low-payout dividend, opportunistic buyback, fast delevering, and per-share/returns-based comp. Two watch-items: (1) $2B of idle cash is deployment risk — the temptation to do a larger, pricier deal that drags ROIC toward the peer-group trap; and (2) the absence of any insider conviction buying. Net: a good capital allocator, early in its standalone life, with the incentives pointed the right way.

8. Changes and Headwinds — Last Two Years

Structural / corporate.

• The spin itself (Sept-30-2023) — clean separation from Danaher (1 VLTO per 3 DHR), ~$2.6B of notes issued, no ongoing Rales control. Post-spin transition-services, tax-matters, and IP agreements are largely wound down.
• Fast delevering — net debt $1.9B → $0.6B (FY23→FY25); the single biggest driver of the standalone financial re-rating.
• First capital return — dividend initiation and +18% raise; first-ever $750M buyback (Nov-2025).
• M&A cadence — TraceGains (2024), In-Situ + GlobalVision (2026); ~$1B deployed with $2B still on the balance sheet.
• Cost-optimization program (Q1-2026) — restructuring for 2027+ savings, additive to the algorithm.
• June-2026 refinancing — $725M 4.85% notes due 2032 to address the 2026 maturity.

Headwinds.

• Mid-single-digit organic growth — the market’s central worry and the reason for the de-rating.
• PQI packaging & color softness — packaging/color testing/inspection equipment fell high-single-digits in Q1-2026 on weak industrial verticals (automotive, textiles, building materials); management calls it timing/nonrecurring, but whether it is cyclical or structural is an open question (watch Q2-2026).
• Tariffs — Veralto regionalized “more than a dozen production lines” in 2025 (Videojet out of China, Trojan Canada→US); FY25 tariff impact was net neutral to EPS, and 2024 tariffs roll off in H2-2026. A managed, not existential, headwind.
• China — a “more mature” market with stalled municipal water funding; WQ down low-single, PQI up on easy comps. Not a growth engine.
• Idle-cash deployment risk — $2B of cash pressures management to act; a large, full-priced deal would be the key capital-allocation risk.

Verdict: net thesis-neutral-to-modestly-strengthening. The corporate changes (delevering, capital return, disciplined M&A, cost program) strengthen the standalone franchise; the headwinds (slow growth, PQI softness, China) are real but manageable and largely already in the price. The two-year record is of a spin executing competently and building optionality.

9. Risk Analysis

Overall: a low-catastrophe-risk, moderate-de-rating-risk profile. The dominant real risks are (1) growth disappointment triggering further multiple compression and (3) a value-destructive large acquisition of the idle cash. Neither threatens the franchise; both threaten the return.

10. Valuation Discussion (Embedded Expectations)

Where it trades (July 2, 2026, $92.55). EV ~$23.2B; ~16.8x TTM EV/EBITDA; ~24x trailing P/E (~21–22x forward on ~$4.24 FY26 adjusted EPS); ~4.1x EV/sales; ~21.7x P/FCF; ~4.6% FCF yield; ~0.55% dividend yield. On its own (short) history these are the cheapest-ever levels — own-history valuation percentiles: P/E 12th, P/B 13th, P/S 24th, composite 16th. The EV/EBITDA multiple has compressed from ~21x (FY24 peak) to ~16.8x while EPS rose ~11% — a pure de-rating.

Relative to peers.

(Peer figures drawn from public filings and financial databases; some approximate.)

The read. Veralto trades mid-pack on EV/EBITDA but posts the highest reported ROIC in the cohort (~19%) — dramatically above the serial-acquirer peers because it carries far less goodwill relative to earnings and leans on high-margin recurring consumables. That is a genuine capital-efficiency tell, not an accounting artifact, and it defends a premium to Xylem (lower-return, more cyclical, more hardware). Veralto is cheaper than Ecolab/Mettler/Waters on essentially every multiple despite comparable-or-better returns and durability, and roughly in line with parent Danaher. It is neither the richest nor the cheapest water name — it is the highest-quality-per-dollar one.

Embedded expectations. At ~24x P/E / ~16.8x EBITDA / ~4.6% FCF yield, the market is underwriting roughly: mid-single-digit organic revenue continuing indefinitely, ~25–50bp/yr of margin expansion, ~10% adjusted-EPS compounding via the price+margin+tax+buyback+M&A algorithm, and no multiple re-rating. That is a reasonable-to-conservative bar for a ~19%-ROIC, 60%-gross-margin, 0.5x-levered, ~61%-recurring franchise. What the market may be pricing incorrectly: (a) it extrapolates mid-single-digit organic as a permanent ceiling and assigns little value to the secular water optionality (PFAS/emerging-contaminant monitoring, reuse, data-center water, In-Situ/GlobalVision); (b) it treats the 2027 cost-optimization program (undisclosed size) as a free option; © it discounts the reload capacity of a 0.5x-levered balance sheet with $2B cash for accretive M&A. What it is pricing correctly: growth is genuinely mid-single-digit, PQI packaging/color is soft, insiders aren’t buying, and there is no near-term catalyst.

Scenario sketch (illustrative; no price target).

• Bear: organic decelerates to ~2–3%, PQI stays soft, margins flat; ~$4.10 FY26 adjusted EPS flat-lining, multiple compresses to ~19–20x → downside toward the low-$80s.
• Base: ~4–5% organic, the algorithm delivers ~$4.24 FY26 adjusted EPS and ~9–10%/yr thereafter, multiple holds ~22–24x → high-$90s to ~$105 over time.
• Bull: water tailwinds inflect organic to ~6–7%, cost program + accretive M&A add, and the multiple re-rates toward Ecolab-quality ~26–28x on demonstrated durability → ~$115–130.

Verdict: a high-quality compounder trading at a discount to its own history and to its closest premium peer (Ecolab), with a defensible — not screaming — margin of safety. The value is quality-at-a-fair-to-cheap price, not deep value; the return depends on the algorithm continuing and, for the upside case, on the growth optionality converting.

11. Variant Perception

Consensus view. Veralto is a high-quality, defensive, Danaher-pedigree water-and-product-ID compounder with a great balance sheet and mid-single-digit growth — “nice business, fully-to-fairly valued, nothing to do.” The stock’s de-rating and the negative Growth/Momentum factor loadings show a market that has quietly demoted it from “premium quality growth” to “boring low-vol quality.”

Strongest bull case. You are buying the highest-return water franchise in the public market at its cheapest-ever multiple. ~19% ROIC (double WACC, and 2–3x the goodwill-laden peers), 61% recurring razor/blade revenue, ~60% gross margins, ~108% FCF conversion, negligible amortization (so the earnings are real), and a 0.5x-levered balance sheet with $2B of dry powder and a fresh buyback. The secular water tailwinds (PFAS, reuse, data-center water) are genuine call options on a growth re-acceleration you are not paying for, and the VES flywheel + disciplined tuck-in M&A compound the algorithm. At ~22x forward adjusted EPS for a franchise this clean, a modest re-rate toward Ecolab-quality peers plus ~10% EPS growth is a comfortably double-digit annual return with downside protection from the quality and the balance sheet.

Strongest bear case. You are paying ~24x P/E / ~16.8x EBITDA for a mid-single-digit-growth industrial whose “double-digit EPS” is a lever-trick — price, tax, delevering, and buyback that are largely spent (net leverage already 0.5x, tax already low-20s, delevering tailwind mostly over). The next leg of EPS growth must come from a harder mix of ~4–5% organic + margin + M&A, and if organic slips toward ~3% while PQI packaging/color weakness proves structural, the multiple has ample room to compress toward Xylem’s ~14x. Insiders aren’t buying (the CEO is a programmatic seller), there is no catalyst, and $2B of idle cash is a temptation to do a large, ROIC-diluting deal. The secular water tailwinds are real but slow and not yet in the numbers. This is a fine business at a full-enough price with no reason to own it now.

The 3–5 assumptions that matter most.

1. Organic growth stays mid-single-digit (~4–6%), not below 3%. Falsified by: two-plus quarters of sub-3% core with PQI still declining.
2. The EPS algorithm keeps delivering ~10% despite spent levers. Falsified by: a year of high-single-digit-or-worse adjusted-EPS growth as tax/interest tailwinds roll off.
3. Management stays disciplined with the $2B cash. Falsified by: a large (>$2B), full-priced acquisition that drags ROIC below ~15%.
4. The moat holds pricing power (~200bps+/yr without volume loss). Falsified by: pricing rollback or volume loss to competition (especially ChemTreat vs. Nalco).
5. Water-secular optionality eventually converts to organic acceleration. Confirmed by: PFAS/reuse/data-center water becoming a quantified, growing revenue line lifting organic toward ~6–7%.

Factor-positioning read (the tape as evidence). VLTO loads negative on Growth (−0.23) and Momentum (−0.06 to −0.10), positive on Quality (+0.08), and low on beta (~0.8); its factor-similar names are Dividend-Aristocrat, Low-Vol, and Capital-Strength ETFs and S&P Global. Risk-adjusted track record: y1 −9.5%, 6-month −13.5%, but the last quarter +23% (annualized) off the lows; max drawdown ~−25%. Interpretation: the market is treating Veralto as an out-of-favor, low-vol, non-growth quality name — abandoned by growth and momentum investors precisely because it doesn’t accelerate. This is where consensus may be offsides: a genuine ~19%-ROIC compounder priced as a low-vol also-ran, near its cheapest-ever multiple, is the classic setup for patient quality-at-a-price — provided the growth doesn’t roll over. It is decidedly not a momentum trade and not a falling knife (the business is stable and growing); it is neglected quality.

12. Fact vs. Interpretation

13. Open Questions

1. FY2026 adjusted-EPS bridge: how much of the guided ~$4.24 is organic volume vs. price vs. margin vs. buyback vs. the falling tax rate — and is the low-20s tax rate sustainable?
2. PQI packaging & color: is the Q1-2026 high-single-digit decline genuinely timing/nonrecurring, or the start of structural industrial softness? (Watch Q2-2026.)
3. Cost-optimization program: what is the undisclosed dollar size and 2027+ run-rate savings?
4. Cash deployment: with $2B on the balance sheet, what is the M&A pipeline’s size and valuation discipline — is a larger, transformational deal on the table?
5. Data-center water and PFAS: when do these convert from “very small portion / optionality” to a quantified, growing revenue line?
6. Residual Danaher exposure: any material remaining tax-matters/indemnity liabilities from the separation (check 10-K vs. proxy silence)?
7. ChemTreat: is it gaining or losing share against Ecolab/Nalco, and is it a keeper or an eventual divestiture candidate?

14. What Must Be True

Bull case — what must be true:

• Organic revenue growth holds at ~4–6% (ideally inflecting toward ~6–7% as PFAS/reuse/data-center water convert), and PQI packaging/color softness proves cyclical, not structural.
• The adjusted-EPS algorithm keeps delivering ~10% via margin, price, disciplined M&A, and buyback even as the tax and delevering tailwinds fade.
• Management deploys the $2B cash into accretive, ROIC-preserving tuck-ins (not a large dilutive deal), and the buyback is sustained.
• The moat holds ~200bps+ annual pricing without volume loss.
• Falsification test: two or more consecutive quarters of sub-3% organic growth with PQI still declining, OR a year of high-single-digit-or-worse adjusted-EPS growth — either would break the “quality compounder” thesis and justify further de-rating.

Bear case — what must be true:

• Organic growth slips toward ~3% as the water-secular narrative fails to convert and PQI weakness persists.
• The spent levers (tax already low-20s, net leverage already 0.5x) leave EPS growth decelerating to mid-single-digit, exposing the ~24x multiple.
• The market continues to rotate out of low-vol, non-growth quality, compressing the multiple toward Xylem’s ~14x.
• Falsification test: organic growth re-accelerates above ~6% (a quantified PFAS/reuse/data-center water revenue line), OR the multiple re-rates toward Ecolab-quality peers on demonstrated durability — either would break the “full price, no catalyst” bear thesis.

15. Source Appendix

Primary sources: Veralto 10-K filings (FY2023–FY2025), 10-Q filings, 8-K material-event filings, the 2026 DEF 14A proxy, and the Form-3/4/5 insider corpus — all mirrored locally from SEC EDGAR (CIK 0001967680). Quantitative data cross-checked against public financial databases (financials, profitability ratios, enterprise value, valuation multiples), market price history, and a public factor/risk model (factor loadings and risk-adjusted track record). Q4-2025 (Feb-4-2026) and Q1-2026 (Apr-29-2026) earnings-call transcripts. Industry/market data: FutureMarketInsights, MarketsandMarkets, MordorIntelligence, Fortune Business Insights, and related 2026 market research. Regulatory context: EPA (PFAS MCL, Lead & Copper Rule Improvements), IIJA water funding. Peer comparables (Xylem, Ecolab, Danaher, Mettler-Toledo, AMETEK, Roper, Waters) drawn from public filings and financial databases.

APPENDIX A — Standard Diligence Questionnaire

Supplemental to the research memo. Report date July 4, 2026. Fact / Interpretation / Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company? The dominant debate is quality vs. price and growth: given a ~19% ROIC, 61%-recurring, fortress-balance-sheet franchise, is ~24x P/E / ~16.8x EBITDA cheap (highest returns in the group, cheapest-ever on own history) or full (mid-single-digit organic growth, lever-driven EPS with the levers largely spent)? Sub-questions: (a) decompose the FY26 adjusted-EPS bridge — how much is organic volume vs. price/tax/buyback? (b) is PQI packaging/color weakness cyclical or structural? © what does management do with $2B of idle cash? (d) when does the water-secular optionality (PFAS, reuse, data-center water) convert to organic acceleration?

Cyclicality & Earnings Nature

Cyclical high or low? Mid-cycle, not extreme. ~61% recurring consumables/service insulates earnings; the cyclical exposure is concentrated in PQI packaging/color (industrial verticals — auto, textiles, building) and, modestly, industrial WQ. Margins are near the high end of the short public history (gross 59.9% vs 56.7% at spin), so there is some margin-cycle richness, but nothing like a peak-earnings distortion. (Interpretation.)

Driven by external environment or internal actions? Both — but tilted internal. Revenue growth is external (water regulation, packaging volume) and mid-single-digit; the earnings growth is largely internal/self-help (VES margin expansion, price, delevering, tax planning, buyback). (Interpretation.)

How stable are revenues? Very stable — ~61% recurring, ~80% tied to water/food/essential goods, no customer concentration (>149,000 WQ customers), and opex-driven (consumables/compliance) rather than lumpy municipal capex. Among the more defensive revenue bases in the industrial complex. (Fact/Interpretation.)

Outlook for products/services; how big is the market? Water analytics ~$4–5B (~5.5% CAGR), UV disinfection ~$3.9B (~15% CAGR), industrial water chemicals ~$40B (~5%), marking & coding ~$7.8B→$13.8B by 2035. Growing, global, structurally attractive, but mid-single-digit for Veralto’s blended exposure. (Fact.)

Business Quality & Competitive Moat

Industry getting more or less competitive? Stable-to-consolidating. Water analytics and marking & coding are consolidated oligopolies (Hach #1 ~16%; Videojet #1 CIJ); industrial water chemicals is fragmented and Ecolab/Nalco-dominated (ChemTreat’s competitive headwind). (Fact/Interpretation.)

How profitable is the business (ROIC/ROE)? Very. Reported ROIC ~18.8% (double WACC), both segments ~25% operating margin, gross margin ~60%, ~108% FCF conversion. ROE ~70% is distorted by thin/negative tangible equity — use ROIC. (Fact.)

How profitable is the industry — competitors, barriers? High-return, high-barrier in analytics/coding (installed base, razor/blade consumables, regulatory method lock-in, service scale); lower-return/more-competitive in industrial water chemicals. (Interpretation.)

Can the business be easily understood? Yes — instruments + consumables + service + software across water and product-ID; a clean razor/razorblade model. (Fact.)

Undermined by foreign low-cost labor? No — the moats are installed base, regulatory validation, service density, and consumable attach, not labor cost. (Interpretation.)

Do brands matter? Yes — Hach, Trojan, Videojet, and Pantone are specified by name and are category leaders; Pantone is a de facto global standard. (Fact/Interpretation.)

Nature of competition / switching costs? Competition is on uptime, service, regulatory validation, and reliability more than price. Switching costs are genuine: re-validating an EPA-approved water-test method or replacing an installed coding line (line-downtime risk) is costly and slow. (Interpretation.)

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The installed base of Hach analyzers and Videojet coders — the source of the recurring consumable annuity — is not capitalized as an asset; it is the real (unbooked) economic moat. (Interpretation.)

Off-balance-sheet liabilities? Operating/finance leases (~$206M capital leases). Residual Danaher separation tax-matters/indemnity exposure is an open item to confirm in the 10-K (not itemized in the 2026 proxy). No pension or unusual off-balance-sheet exposure flagged. (Fact/Open question.)

How conservative is the accounting? Conservative and clean — negligible acquisition-intangible amortization (~$36M), GAAP EPS within ~4% of adjusted, SBC small (1.3%) and excluded from FCF, ~108% FCF/NI conversion (cash exceeds GAAP earnings). (Fact.)

How CapEx-hungry? Minimal — capex ~1.1% of sales ($63M FY25). Highly asset-light. (Fact.)

Capital Allocation & Management

How much FCF, and how is it used? ~$1.0B FCF FY25. Priorities: disciplined tuck-in M&A first (In-Situ ~$427M, GlobalVision, TraceGains), a low-payout growing dividend (+18% to $0.13/qtr, ~11–12% payout), first-ever $750M buyback (Nov-2025), and delevering. (Fact.)

Significant acquisitions recently? TraceGains (~$349M, 2024), In-Situ (~$427M, 2026), GlobalVision (2026), AQUAFIDES (small). ~$1B deployed by Q1-2026; $2B cash remains. (Fact.)

Buying back shares? Yes — first-ever $750M authorization (Nov-2025), largely spent by Q1-2026; opportunistic/residual, not a primary policy. (Fact.)

Issuing large amounts of stock to insiders? No — SBC is modest ($74M, 1.3% of sales); share count roughly flat (~248M). (Fact.)

Compensation policy / incentive alignment? Strong and per-share-oriented: bonus on Adjusted EPS (40%) + Core organic Revenue Growth (40%) + FCF Conversion (20%); LTI 50% PSUs on relative TSR + a ±10% ROIC modifier / 25% options / 25% RSUs. No size/empire metric. CEO 90% at-risk. One soft spot: ROIC only a modifier, not a primary gate. (Fact/Interpretation.)

Motivations of management? Professional Danaher-lineage operators (CEO Honeycutt ex-Danaher); insiders own <1%, no founder block — competent stewards, but not owner-operators with large skin in the game. No discretionary insider buying; CEO is a programmatic 10b5-1 seller. (Fact/Interpretation.)

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard US C-corp common stock (NYSE: VLTO), 1099 dividend reporting. (Fact.)

Dividend policy? Initiated post-spin, raised +18% to $0.13/qtr; ~0.55% yield, ~11–12% payout (deliberately low to preserve M&A firepower). (Fact.)

How profitable is the business? ~23% operating margin, ~17% net margin, ~19% ROIC — highly profitable. (Fact.)

Net income diverging from cash from operations? No — favorably aligned: FCF ~108% of net income, OCF $1,077M vs NI $940M. Clean earnings quality. (Fact.)

Risks & Downside

What would cause the stock to decline? (1) Organic growth stalling below ~3% and/or PQI weakness proving structural → further multiple de-rate; (2) a large, full-priced acquisition dragging ROIC; (3) a market rotation out of low-vol quality; (4) the falling tax rate / spent delevering exposing decelerating EPS growth. (Interpretation.)

Risk of catastrophic loss? Very low — diversified, recurring, cash-generative, investment-grade, essential end-markets. (Interpretation.)

Chance of a total loss? Negligible — no plausible path to permanent capital impairment given the balance sheet and business quality. (Interpretation.)

Recent News & Events

Has the business environment changed recently? Incrementally: fast delevering (net debt $1.9B→$0.6B), first dividend raise (+18%) and first buyback ($750M), ~$1B of tuck-in M&A (In-Situ, GlobalVision), a new cost-optimization program (2027 benefit), and a June-2026 refinancing ($725M 4.85% notes due 2032). PQI packaging/color softened in Q1-2026. Tariffs managed to net-neutral. (Fact.)

Significant acquisitions / accounting changes / new markets? M&A as above; no accounting-policy changes; data-center water and PFAS monitoring are nascent new vectors (optionality, not yet material). (Fact.)

APPENDIX B — Source Appendix

Report date July 4, 2026. Primary sources first; third-party aggregators labeled. Price reference $92.55 (July 2, 2026).

Primary — SEC filings (EDGAR, CIK 0001967680; mirrored locally to SEC EDGAR)

• Form 10-K FY2025 (filed 2026-02-20, vlto-20251231.htm) — segment revenue/operating profit (WQ $3,321M / PQI $2,182M), recurring-revenue disclosure (~61%), geographic mix, goodwill ($2,838M) and intangibles ($524M gross; $216M net finite-lived + $308M indefinite), amortization (~$36M), R&D ($266M), debt schedule, balance sheet.
• Form 10-K FY2024 (filed 2025-02-25) and FY2023 (filed 2024-02-28) — trend data; spin/separation disclosures.
• Form 10-Q filings (2024–2026) — quarterly segment and cash-flow detail.
• 8-K material events — spin completion (Sept-30-2023), notes issuance, TraceGains acquisition (~$349M, Oct-2024), In-Situ (~$427M, 2026) and GlobalVision (2026) acquisitions, $750M buyback authorization (Nov-2025), +18% dividend increase (Q4-2025), $725M 4.85% senior notes due 2032 (June-2026), earnings releases and guidance.
• DEF 14A proxy (filed 2026-03-27, vlto-20260326.htm) — executive compensation structure and incentive metrics (Adjusted EPS 40% / Core Revenue Growth 40% / FCF Conversion 20% bonus; 50% PSU relative-TSR + ROIC modifier / 25% options / 25% RSUs LTI); CEO/CFO pay ($14.8M / $5.3M); ownership (insiders <1%; Vanguard 11.8%, BlackRock 9.6%, T. Rowe 4.3%); board composition (12 directors, staggered; ex-Danaher directors Comas and King); comp peer group (16 companies).
• Form 3/4/5 insider corpus (135 Form 4s since spin) — code totals A=205, S=63, F=33, M=32, P=1 (a single nominal 9-share director purchase); CEO Honeycutt a recurring 10b5-1 net seller.

Primary — Earnings-call transcripts (company earnings calls)

• Q1-2026 call (Apr-29-2026) — FY26 adjusted-EPS guide raised to $4.20–$4.28; segment trajectory; In-Situ/GlobalVision; cost-optimization program; tariff/China commentary; data-center water.
• Q4-2025 call (Feb-4-2026) — FY25 results (adj EPS ~$3.90, +10%); initial FY26 guide ($4.10–$4.20); capital-allocation framework; buyback/dividend.
• Q3-2025, Q2-2025 earnings calls (trend).

Quantitative cross-checks (third-party aggregated data — reconciled to filings)

• Public financial databases — income statement, balance sheet, cash flow (FY2022–FY2025); profitability ratios (ROIC ~18.8%, margins); enterprise value (EV ~$23.2B TTM); valuation multiples; per-share and credit ratios. Third-party; primary EDGAR filings govern where they differ.
• Market price data — daily price/OHLCV history (2023-09-27 → 2026-07-02; ATH $113.60 Oct-2024; low $67.51 Nov-2023); own-history valuation percentiles (P/E 12th, P/B 13th, P/S 24th, composite 16th).
• Factor/risk model — factor loadings (beta ~0.8; +Quality, −Growth, −Momentum); leaderboard (y1 −9.5%, m6 −13.5%, m3 +23% annualized; max DD ~−25%); related stocks (FTCS, NOBL, KNG, LGLV, SPGI); idiosyncratic vol ~19.8%.

Industry / market data (third-party, 2026)

• Water analytics & instruments: FutureMarketInsights, CongruenceMarketInsights, CoherentMarketInsights (~$4–5B, ~5.5% CAGR; Hach #1 ~16%).
• Industrial water-treatment chemicals: MarketsandMarkets, MordorIntelligence, EmergenResearch (~$40B; Ecolab/Nalco, Kurita, Solenis, Veolia, Kemira).
• UV disinfection: MordorIntelligence, SNS Insider, GMInsights (~$3.9B, ~15% CAGR; Trojan top-2 vs Xylem/Wedeco).
• Marking & coding: FutureMarketInsights, ResearchAndMarkets, Fortune Business Insights (~$7.8B→$13.8B; Videojet #1 CIJ vs Markem-Imaje/Dover, Domino/Brother).
• Regulatory: US EPA (PFAS drinking-water MCL 2024; Lead & Copper Rule Improvements); IIJA/Bipartisan Infrastructure Law water funding.